放疗联合热疗治疗难治性复发性盆腔恶性肿瘤的疗效及安全性

Efficacy and safety of radiotherapy combined with hyperthermia in the treatment of refractory recurrent pelvic malignancies

目的探讨放疗联合热疗治疗难治性复发性盆腔恶性肿瘤的疗效及安全性。方法选取66例难治性复发性盆腔恶性肿瘤,根据治疗方式分为观察组(n=34)和对照组(n=32),对照组患者给予放疗,观察组患者给予放疗联合盆腔部位热疗。比较两组患者的临床疗效、生活质量[肿瘤患者生活质量量表(QOL)]、不良反应和远期生存率。结果观察组患者的治疗总有效率为70.59%,高于对照组患者的43.75%(P﹤0.05)。治疗后,两组患者QOL量表各维度评分均明显高于本组治疗前(P﹤0.01),且观察组患者QOL量表各维度评分均明显高于对照组(P﹤0.01)。观察组患者的不良反应总发生率为11.76%,低于对照组患者的34.38%(P﹤0.05),3年生存率为82.35%,高于对照组患者的59.38%(P﹤0.05)。结论放疗联合热疗能够明显提高难治性复发性盆腔恶性肿瘤的临床疗效,减少放疗不良反应,提高患者的生活质量和远期生存率。

Objective To investigate the efficacy and safety of radiotherapy combined with hyperthermia in the treat-ment of refractory recurrent pelvic malignant tumors.Method A total of 66 patients with refractory and recurrent pelvic malignancies were selected and divided into observation group(n=34)and control group(n=32)according to the treat-ment methods.The patients in the control group were given radiotherapy,and the patients in the observation group were given radiotherapy combined with pelvic hyperthermia.The clinical efficacy,quality of life[cancer patients of quality of life scale(QOL)],adverse reactions and long-term survival rates were compared between the two groups.Result The to-tal effective rate of the observation group was 70.59%,which was higher than 43.75%of the control group(P<0.05).Af-ter treatment,the scores of each dimension of the QOL scale in the two groups were significantly higher than those before treatment in the same group(P<0.01),and the scores of each dimension of the QOL scale in the observation group were significantly higher than those in the control group(P<0.01).The total incidence of adverse reactions in the observation group was 11.76%,which was lower than 34.38%in the control group(P<0.05),and the 3-year survival rate was 82.35%,which was higher than 59.38%in the control group(P<0.05).Conclusion Radiotherapy combined with hyperthermia can significantly improve the clinical efficacy of refractory and recurrent pelvic malignancies,reduce adverse reactions to radiotherapy,and improve patients’quality of life and long-term survival.